Rex Largen, MD
Dermatology · Lincoln, NENPI 1326036112
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $22,158 of the $25,684 with a category attached, or 86.3%. It is spread thinly across 37 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,885, 3.3 times the $1,783 reported in 2019. Among dermatology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,377 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$4K
- AbbVie$4K
- Johnson & Johnson$3K
- Lilly USA, LLC$2K
- Sun Pharmaceutical Industries Inc.$2K
- Regeneron Healthcare Solutions, Inc.$2K
- plus $10K from 31 others
Across 147 payments — averaging $4754.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$639K
- Pfizer$60K
What the payments were for
- Consulting fees$2,92311%
- Food & beverage$22,15886%
- Education$6032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 71 | $4,245 |
| AbbVie | 234 | $4,081 |
| Johnson & Johnson | 164 | $2,546 |
| Lilly USA, LLC | 91 | $1,718 |
| Sun Pharmaceutical Industries Inc. | 90 | $1,566 |
| Regeneron Healthcare Solutions, Inc. | 83 | $1,512 |
| Novartis | 84 | $1,398 |
| Mayne Pharma Commercial LLC | 65 | $1,109 |
| Sanofi | 56 | $1,102 |
| Pfizer | 105 | $1,076 |
| Amgen | 56 | $972 |
| Incyte Corporation | 40 | $764 |
| E.r. Squibb & Sons, L.L.C. | 48 | $687 |
| LEO Pharma Inc. | 30 | $556 |
| Galderma Laboratories, L.p. | 36 | $498 |
| Dermavant Sciences, Inc. | 41 | $460 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 23 | $322 |
| Genentech USA, Inc. | 8 | $164 |
| Boehringer Ingelheim | 7 | $137 |
| Almirall LLC | 6 | $109 |
| Arcutis Biotherapeutics, Inc. | 5 | $89 |
| Bristol Myers Squibb | 5 | $88 |
| ANI Pharmaceuticals, Inc. | 4 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Organon | 5 | $53 |
| Botanix SB Inc | 2 | $43 |
| VYNE Pharmaceuticals Inc. | 2 | $37 |
| Sandoz | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Dermira, Inc. | 2 | $26 |
| Regeneron | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Organogenesis Inc. | 1 | $21 |
| Genentech, Inc. | 1 | $17 |
| Promius Pharma LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Biofrontera Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimzelx$1,403
How this compares
$25,684 in reported general payments places this provider in the 90th percentile of 68 dermatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 16 | $322,421 |
| TremfyaGuselkumab | 17 | $254,808 |
| Humira(Cf) PenAdalimumab | 14 | $96,704 |
| EnbrelEtanercept | 12 | $88,271 |
| Dupixent PenDupilumab | 12 | $52,997 |
| Dupixent SyringeDupilumab | 11 | $46,074 |
| Doxycycline Monohydrate | 344 | $8,800 |
| Betamethasone Dipropionate | 152 | $5,841 |
| Clobetasol Propionate | 90 | $5,830 |
| Tacrolimus | 58 | $5,029 |
| Ketoconazole | 177 | $3,943 |
| Fluticasone Propionate | 161 | $3,577 |
| Doxycycline Hyclate | 98 | $2,808 |
| Triamcinolone Acetonide | 253 | $2,713 |
| Fluorouracil | 25 | $2,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,546 | $254,80817 claims |
| AmgenEnbrel | $972 | $88,27112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 dermatology providers in Nebraska.
Other dermatology in Lincoln
- Casey BowenLincoln$51K
- Lauren StephensLincoln$18K
- Gina WeirLincoln$10K
- Margaret SuttonLincoln$7K
- Nicolette NetzLincoln$7K
- Rodney BaslerLincoln$5K
- Mark HeibelLincoln$2K
- Brian HerbinLincoln$2K
- Tyler EvansLincoln$2K
- Rudolf StrnotLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.